Clinical Research Fellow, Urogynaecology, University Hospitals Coventry and Warwickshire, UK.
Consultant Gynaecologist and Subspecialist Urogynaecology, University Hospitals Coventry and Warwickshire, UK.
Eur J Obstet Gynecol Reprod Biol. 2022 Sep;276:69-73. doi: 10.1016/j.ejogrb.2022.07.001. Epub 2022 Jul 5.
Urinary incontinence and prolapse are debilitating conditions significantly affecting quality of life. They are extremely prevalent, affecting a significant number of women attending gynaecology clinics with complex symptoms. ePAQ-PF offers a user-friendly clinical tool, which provides valid and reliable data. The system offers comprehensive symptoms and quality of life evaluation which is an advantage over history and may enhance the clinical episodes detection as well as the quality of care for women with pelvic floor disorders. The aim of the study is to compare effectiveness of ePAQ-PF against history for diagnosis in complex urogynaecology patients.
Data was collected retrospectively from ePAQ-PF and history in a tertiary level urogynaecology unit and collated onto microsoft excel. 40 patients were selected randomly from 56 eligible (administered and succeessfully completed ePAQ-PF) patients attending Urogynaecology and PEARL (combined urogynaecology and colorectal) clinics between July 2018 and July 2021. Fisher's exact test was used for inferring on statistical significance in the comparative analysis. The software used for this analysis was SAS version 9.4.
Thirty-four out of the forty patients were eligible for analysis for overactive bladder and stress urinary incontinence; twenty-four for prolapse and twenty-six patients for voiding difficulty. Patients were between 18 and 80 years of age with highest participants between 40 and 69 years. Four scored symptom domain was chosen for statistical analysis due to adequate power of comparative data in these domains. The additional diagnostic yield by ePAQ-PF for overactive bladder (OAB), stress urinary incontinence (SUI), voiding difficulty (VD) and prolapse was 26.47%, 0%, 67% and 16.67% respectively. P value for OAB, VD and prolapse was 0.0294, 0.0031 and 0.01 respectively. Apart from these four symptoms ePAQ-PF contributed additional symptoms over and above history in all 40 patients due to its wide range of symptom domains. History provided additional symptoms in 3 women with recurrent urinary tract infection which was not identified on ePAQ-PF.
ePAQ-PF has shown significant additional diagnostic yield for overactive bladder, voiding difficulty and prolapse. P value for each has supported this statement. Although there was no additional diagnostic yield for stress urinary incontinence by ePAQ-PF, it has shown an accuracy of 96.97% (n = 33) for diagnosing the cases like history taking for SUI. ePAQ-PF enabled us to identify more symptoms in 100% cases (n = 40) which includes body image, general sex life, pain and altered sensation of vagina, reduced capacity of vagina etc, in comparison to history, for complex urogynaecology patients. History contributed to additional symptom diagnosis such as recurrent urinary tract infection in 7.5% (n = 40) of cases.
ePAQ-PF is a useful diagnostic tool providing additional benefit for the diagnosis of the complex urogynaecology patient. Overall recommendation is to implement a policy of using ePAQ-PF evaluation in all complex urogynaecology patients in addition to history. Further studies are needed to assess the pattern of the yield across age, parity, disease severity related to complex urogynaecology symptoms.
尿失禁和脱垂是使人虚弱的疾病,严重影响生活质量。它们非常普遍,影响了许多到妇科诊所就诊的患有复杂症状的女性。ePAQ-PF 提供了一个用户友好的临床工具,提供了有效和可靠的数据。该系统提供了全面的症状和生活质量评估,这是其优于病史的一个优势,并且可以提高对盆底功能障碍患者的临床发作检测和护理质量。本研究的目的是比较 ePAQ-PF 在复杂尿失禁患者诊断中的有效性。
从三级尿失禁单位和 PEARL(泌尿科和结直肠科联合)诊所的 ePAQ-PF 和病史中回顾性收集数据,并整理到 Microsoft Excel 中。从 2018 年 7 月至 2021 年 7 月期间,56 名接受并成功完成 ePAQ-PF 评估的符合条件的患者中随机选择了 40 名患者。使用 Fisher 确切检验推断比较分析中的统计学意义。用于此分析的软件是 SAS 版本 9.4。
在 40 名患者中,有 34 名患者符合评估急迫性尿失禁和压力性尿失禁的条件;24 名患者符合脱垂标准,26 名患者符合排尿困难标准。患者年龄在 18 岁至 80 岁之间,最高年龄在 40 岁至 69 岁之间。由于这些领域的比较数据具有足够的功效,因此选择了四个评分症状领域进行统计分析。ePAQ-PF 对急迫性膀胱过度活动症(OAB)、压力性尿失禁(SUI)、排尿困难(VD)和脱垂的额外诊断收益分别为 26.47%、0%、67%和 16.67%。OAB、VD 和脱垂的 P 值分别为 0.0294、0.0031 和 0.01。除了这四个症状外,ePAQ-PF 还通过其广泛的症状领域,为所有 40 名患者提供了额外的症状。由于病史提供了 3 名复发性尿路感染女性的额外症状,而这些症状在 ePAQ-PF 上没有被识别。
ePAQ-PF 对急迫性膀胱过度活动症、排尿困难和脱垂具有显著的额外诊断收益。每项指标的 P 值都支持这一说法。尽管 ePAQ-PF 对压力性尿失禁没有额外的诊断收益,但它对 33 例(n=33)像病史采集一样诊断 SUI 的病例的准确率为 96.97%。ePAQ-PF 使我们能够在 100%的病例(n=40)中识别更多的症状,包括身体形象、一般性生活、阴道疼痛和感觉改变、阴道容量减少等,与病史相比,用于复杂的泌尿科患者。病史在 7.5%的病例(n=40)中有助于诊断复发性尿路感染等额外症状。
ePAQ-PF 是一种有用的诊断工具,为复杂的泌尿科患者的诊断提供了额外的益处。总体建议是在病史之外,为所有复杂的泌尿科患者实施使用 ePAQ-PF 评估的政策。还需要进一步研究,以评估在年龄、产次、与复杂泌尿科症状相关的疾病严重程度方面的收益模式。